<u>Rift Valley fever: surveillance</u> measures assessed



EFSA has completed its series of assessments on Rift Valley fever (RVF) with a scientific opinion looking at the <u>effectiveness of surveillance and control</u> measures in the EU.

The latest opinion follows two opinions published earlier this year which assessed respectively the <u>risk of introduction of RVF to the EU</u> and the <u>impact of the disease in the French overseas department of Mayotte</u>.

Background

Rift Valley fever is a vector-borne disease transmitted by mosquitoes to animals — domestic and wild ruminants and camels — and humans.

The disease is endemic in sub-Saharan Africa and in the Arabian Peninsula, but has never been reported in continental Europe although its range is expanding. In 2018-19 it reappeared after ten years in Mayotte, where there have been outbreaks involving multiple human cases.

• <u>Rift Valley fever — assessment of effectiveness of surveillance and control measures in the EU</u>